



Translational Research

Alcohol • Drugs • Toxicology

Annual Report

2021

Contents

About the Edith Collins Centre	3
Research overview.....	3
Research collaborations.....	6
Medical education and training.....	7
ECC achievements in 2021.....	8
Grant Funding.....	9
Awards	17
Publications	18
Staff.....	34

About the Edith Collins Centre

The Edith Collins Centre (ECC) conducts translational research in the fields of alcohol, drugs and toxicology to drive change in policy and practice and to improve the health of those affected by alcohol, drugs and poisoning.

ECC was established as a partnership between Sydney Local Health District (SLHD) and the University of Sydney to increase clinical research capacity in alcohol, drugs, and toxicology.

Our multidisciplinary research encompasses a broad range of disciplines including clinical toxicology, addiction medicine, public health, epidemiology, hepatology, mental health, and Aboriginal and Torres Strait Islander health. Our research ranges from early interventions for drug and alcohol use, through to genetic and molecular mechanisms of tissue injury and clinical trials in the treatment of substance use disorders.

ECC comprises several highly successful research groups conducting nationally and internationally leading work in these areas, achieving world-first outcomes in their fields, including the establishment of notable international collaborations and consortia and large multi-national cohorts.

Our work is mainly supported by external peer-reviewed grants. ECC Staff Specialists also provide leadership and teaching in the speciality of Addiction Medicine at the University of Sydney.

Research overview

ECC research is aligned across the following five key areas of research:

- **Clinical Toxicology and Pharmacology** (Prof Andrew Dawson, Prof Nick Buckley, A/Prof Darren Roberts)
- **Indigenous Health and Substance Use** (Prof Kate Conigrave, A/Prof Kylie Lee, Dr Michael Doyle)
- **Alcohol Biology, and Genetics** of Liver Disease (A/Prof Devanshi Seth, Prof Paul Haber)
- **Clinical Research in Alcohol, Addictive Behaviours & Treatment** (A/Prof Kirsten Morley, Prof Paul Haber, Prof Andrew Baillie, Dr Warren Logge)
- **Illicit Drug Use** (A/Prof Carolyn Day)

Clinical Toxicology includes acute and chronic medicine and chemical poisoning, serious adverse prescribed and non-prescribed drug reactions, and toxicology that contributed to a substantial source of morbidity and mortality across the world.

The team, led by Professors Andrew Dawson and Nick Buckley, has established large prospective cohorts of acute poisoning and developed treatment guidelines resulting in national and international policy and regulatory changes.

Much of their national research is based on detecting early signals of significant drug toxicity and measuring the public health impact of regulatory change. This group has led the development of the NSW Poisons Information Centre research program and used data to describe many developing trends in poisoning including pharmaceuticals and drug use.

The team has been funded by NHMRC Program and CRE Grants (CRE in Medicines Intelligence, and CRE in Translational Venom and Antivenom Research) along with project grants and other forms of support.

Recent activities

- The Australian Toxicology Monitoring (ATOM) and Australian Snakebite Projects (ASP), which identify the clinical effect and response to treatment from various poisonings and snakebites.
- An evaluation of the patterns of use and poisoning with various substances like codeine, paracetamol, pregabalin, etc.
- A randomised stepped wedge trial of scaling up of a community-based alcohol education program in rural Sri Lankan villages, and its effects on alcohol use, associated harms, depression and social capital.
- A comparative study of oral and intravenous antidotes for acute paracetamol poisoning.
- Long-term effects on kidney function and health after severe acute pesticide poisoning and snake envenomation.

Indigenous Health and Substance Use research, led by Professor Kate Conigrave, Associate Professor Kylie Lee and Dr Michael Doyle, involves developing culturally appropriate, accessible and innovative approaches to prevent or treat alcohol or other drug use disorders among Aboriginal and Torres Strait Islander peoples and other priority populations.

Founded on longstanding partnerships with these communities and services across Australia, their focus is on culturally appropriate and relevant work.

Recent activities

- A Centre for Research Excellence (CRE): Indigenous Health and Alcohol was opened in May 2017 to recruit and support Indigenous Australian researchers. The CRE, funded by the NHMRC, aims to reduce alcohol harm experienced by Indigenous Australians, and works to draw on the diverse range of skills among the investigators and the Indigenous research trainees. It combines cultural, community, health service, research and policy expertise. To date the CRE has mentored 9 post-graduate research students, 3 early career researchers, and 3 trainees, all of whom are Aboriginal descent.
- The design of a world-first iPad App that has been shown to be an accurate and acceptable tool to help Aboriginal and Torres Strait Islander peoples to self-report their drinking and provides them with immediate tailored feedback on the App ('brief intervention').
- A cluster randomised trial that examines a model of support for 22 Aboriginal and Torres Strait Islander community controlled primary care services around alcohol care.
- Several studies that are identifying the need for treatment for alcohol use disorders in the NSW prison system, and if there are ways to better meet any unmet need.

Clinical Research in Alcohol, Addictive Behaviours and Treatment is a major area of interest with ongoing randomised control trials, including comorbid substance abuse and suicide risk.

The team, led by Associate Professor Kirsten Morley, is leading world first research into alcohol dependence, alcoholic liver disease and their associated psychological comorbidities.

The team is currently conducting a number of randomised clinical trials testing novel treatments for alcohol addiction, and how to optimise the response to treatment and improve translation of evidence-based approaches into practice.

Recent activities

- | | |
|------------------|--|
| Discovery | <ul style="list-style-type: none">• A study of cannabidiol (CBD) examining the effect of CBD on a range of different functions such as functional connectivity between brain regions, brain activity in response to alcohol and anxiety cues, brain metabolite levels in addition to measures of craving, sleep and mood.• An MRI study comparing the action of topiramate and naltrexone on functional connectivity between brain regions, brain activity in response to alcohol and anxiety cues, brain metabolite levels and the role of genotypes in these actions. |
|------------------|--|

	<ul style="list-style-type: none"> • A predictive MRI study examining neural, cognitive, and epigenetic predictors of response to MDMA assisted exposure therapy to treat comorbid PTSD and AUD.
Treatment	<ul style="list-style-type: none"> • A randomised, double blind, controlled trial comparing naltrexone to topiramate in the treatment of alcohol dependence. It comprises of a 12-week treatment program with study medications (naltrexone or topiramate) and medical management. NHMRC funded. (2019-2021) • A randomised, double blind, controlled trial investigating whether N-acetylcysteine is a safe and effective treatment for reducing heavy alcohol consumption. In this study participants are randomly allocated to N-acetylcysteine or matched placebo and undergo a 12-week treatment program with study medications (NAC or placebo) and medical management.
Translation	<ul style="list-style-type: none"> • National clinical guidelines for treatment of Alcohol problems. The ECC team led a national working group to revise and update these guidelines and generate implementation tools. (2018-2021) • An evaluation of the effectiveness of the Pathways to Comorbidity Care (PCC) training program in improving the management of comorbid substance use and mental disorders using an integrated comorbidity management approach. Both the clinical practice outcomes and the implementation outcomes were evaluated. Funded by the NSW Health Translational Research Grant Scheme. (2017-2020) • Following on from the PCC project, a need assessment of drug and alcohol and mental health nurses is being conducted to inform a process of engaging leadership in implementing an integrated care management approach to comorbid drug and alcohol and mental disorders with nurses. (2021-2023)

Alcohol biology and genetics of liver disease is an important area of research at DHS within the Alcoholic Liver Disease Research Program. The program led by Associate Professor Devanshi Seth, undertakes a range of clinical, fundamental and translational research. This research is internationally recognised for significantly advancing the field by contributing to the understanding of genetics and molecular mechanisms of alcohol-related liver disease (ALD).

Recent activities	
Clinical research	<ul style="list-style-type: none"> • The multinational GenomALC Consortium led by Seth is investigating the genetic/genomic factors associated with the risk of alcoholic cirrhosis across Australia, UK, USA and Europe. The team established the world's largest biobank and database from ~6700 drinkers and identified novel genetic risks associated with alcohol-related cirrhosis. This ongoing research, funded by the National Institutes of Health (NIH)/National Institute on Alcohol Abuse & Alcoholism (NIAAA), USA, continues to explore the genetic architecture of this disease
Fundamental research	<ul style="list-style-type: none"> • This research focuses on understanding the molecular mechanism underlying progression of ALD using experimental models, including animal (mouse, zebrafish) models of fatty liver. Research using state-of-the-art gene-editing tools (Crispr-Cas9) in a zebrafish model of alcohol-induced fatty liver is underway studying the mechanisms of action of the genes (identified through GenomALC findings) involved in lipid (fat) metabolism
Translational research	<ul style="list-style-type: none"> • The GenomALC study developed a novel genetic risk score (GRS) and combined with clinical risk (diabetes) developed a predictive model to identify patients at higher risk of cirrhosis. This novel concept is now being planned for a randomized clinical trial that underpins the implementation of this research with a potential to significantly impact the field of genomics and personalised medicine for ALD patients. • PETH test, a semi-quantitative measure for alcohol use, was established by Dr Seth's research group at RPA Hospital. This test is now routinely used in clinical settings by Drug Health and Liver clinics to determine alcohol use, changing the management of

Alcohol Use Disorder (AUD) patients and used in clinical trials to evaluate alcohol addiction treatment.

Illicit Drug use team (led by Associate Professor Carolyn Day) examines substance use and related harms in vulnerable populations. In particular, it evaluates the influences and improvements to service use and delivery in this area. The program has close connections with the Sydney Women's and Drug Research group (SWaDR) as well as NGOs including Uniting Sydney Medical Supervised Injecting Centre and the NSW Alcohol and Drug Foundation.

Recent activities

- Alcohol and other Drugs Outcomes Register (AoDOR): Health Systems Access and Patient Journey.
- Validation and international comparison of the street value of prescription and illicit drugs using Street Rx data.
- Examining COVID-19 related changes to delivery of opioid agonist treatment.
- Development of a model of care for substance use in pregnancy and parenting for Sydney Local Health District.
- Understanding driving-related safety for individuals who receive opioid agonist treatment (OAT).
- The ADM users into treatment (ADMit) study: linking people who use automatic dispensing machines with the hepatitis c cascade of care.
- Characteristics and needs of women seeking treatment for substance use disorders in NSW.
- Understanding the factors facilitating or hindering utilisation of drug and alcohol services for the Muslim and Arabic speaking community in Sydney.
- Suicide prevention project at Uniting Medically Supervised Injecting Centre (Uniting MSIC).
- Evaluation of drug and alcohol services for young people in Sydney including client and practitioner perspectives, cultural competency and the role of agency and aspiration in youth treatment.

Research collaborations

DHS Research has a number of Translational Research projects that aim to increase uptake of evidence-based treatment. These projects are funded by NHMRC and NSW Health and include:

- increasing uptake of evidence-based treatment for alcohol problems in Australia's First Peoples
- improving the management of comorbid mental health and substance use with an integrated approach (including a multi-modal training package to several sites across NSW Health LHD's)
- a shared care pathway for the treatment of alcohol use disorders in primary care.

DHS is also an active member of the NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN), which is a collaborative network of NSW Local Health District and Health Network services engaged in clinical research in the alcohol and other drug (AOD) sector.

DHS boast many collaborations with external groups:

- Clinical Services of SLHD (Gastroenterology/Liver Services, Emergency Department, Nursing, Pharmacy, Women and Babies Services, Women Children and their Families Institute, Pain Management Services at RPAH and Concord Hospitals, Mental Health Services, Public Health, Community Health, Oral Health and Aged Care, Aboriginal Health)
- HIV and Related Programs (HARP)
- Health promotion

- Other Local Health Districts (South Eastern Sydney LHD, Hunter New England LHD, Northern Sydney LHD and South West Sydney LHD)
- The University of Sydney Matilda Centre
- Brain and Mind Centre
- United Medically Supervised Injecting Centre
- NSW Poisons Information Centre
- National Drug and Alcohol Research Centre (NDARC)
- Centenary Institute of Cancer Medicine and Cell Biology
- South Asian Clinical Toxicology Research Collaboration (SACTRC)
- Burnett Institute, Melbourne
- NSW Alcohol and Drug Foundation
- Network of Alcohol and other Drug Agencies (NADA)
- Redfern Legal Centre
- Youth INsearch
- Blackdog Institute
- NSW Users and AIDS Association (NUAA)
- Aboriginal Drug and Alcohol Council, South Australia
- School of Medicine, Kufa University, Iraq.

Medical education and training

Medical Education is a key focus of the Research Unit. The fields of substance use and related health and social consequences are major topics for undergraduate programs in Medicine and the Health Sciences due to the high prevalence of these issues and their major impact. Our staff are currently teaching in Addiction within the Universities' Faculty of Medicine and Health, across Dentistry, and Pharmacy and Public Health and the brain and mind sciences. A/Prof Day has coordinated addiction medicine education in the Sydney Medical Program since 2007.

All groups are involved in continuously training and teaching medical and science graduates (Honours, Masters, MPhil and PhD) and students in Aboriginal health promotion (GradDipIndigHP). Group members are engaged in the placement of overseas trainees/students, teaching/training of GPs and Aboriginal drug and alcohol workers and other clinicians across Australia. We have developed a Masters in Clinical Toxicology distance learning course and Open-source curriculum, Master of Public Health unit of study "Alcohol, Drugs and Health" and the Addiction unit of study in the Brain and Mind Centre (BMC) post-graduate program. There are opportunities to undertake postgraduate studies in the above areas, from basic science, clinical or public health perspectives.

ECC achievements in 2021



40 active grants



Over \$39 million of active fundings



120 peer-reviewed journal publications



1 book



16 book chapters



52 national and international conference presentations

Grant Funding

New grants awarded 2021

Total new funding commencing in 2022:

\$9,583,936

- **MRFF Innovative Therapies for Mental Illness (2022–2025):** A randomised, double-blind, controlled trial of MDMA assisted exposure therapy for comorbid alcohol use and post-traumatic stress disorder. \$1,951,246. CIA. Awardees: Morley, Mills, Haber, Lubman, Teesson, Arunogiri, Baillie, Yong Yi Lee, Morse, Back
- **NHMRC Synergy Grant (2022–2026):** Linking clinical and basic science discovery to find new treatments for alcohol use disorder. \$5,000,000. CIB. Awardees: Haber, Morley, Lawrence, Manning, Lubman, McNally, Millan, Arunogiri
- **NHMRC Investigator Grant Level 3 (2022–2026):** Applied research to prevent the epidemic of poisoning deaths. \$1,500,000. Awardee: Buckley NA
- **NHMRC Investigator Grant, Emerging Leadership 1 (2022–2026):** Alcohol treatment for Aboriginal men in and out of prison \$607,263. Awardee: Doyle, M
- **ARC Discovery Project (2022–2024):** Investigating Memory Reliability in Intoxicated Witnesses of Crime. \$525,427. Awardees: Monds, Takarangi, Chin, Montebello; PIs: Semrad, Flowe

Ongoing grants

Granting body	Awardees	Project title	Grant total \$	Years	Status
NHMRC/Clinical Trials and Cohort Studies	Baillie A, Morley K, Haber P, Slade T	A randomised controlled trial of N-acetylcysteine for the treatment of alcohol use disorder	\$1,329,000	2021-2025	New-Awarded in 2021
NHMRC Ideas Grant	Withall, Schofield, Ginnivan, Hwang; Als: Butler, Snoyman, Greenberg, Monds, Radford, Dingwall, Howie, Reutens	ASCAPE: Audio App-delivered Screening for Cognition and Age-related Health in Older Prisoners	\$844,050	2021-2023	New-Awarded in 2020
Cystic Fibrosis Australia	Ooi, van Dorst, Katz, Sivam, Taylor, Haber, Jaffe, Thomas	Short chain fatty acids and gastrointestinal complications in cystic fibrosis	\$50,000	2021-2022	New-Awarded in 2020
NSW Ministry of Health	Day CA, Roxburgh A, Haber PS, Reid SE, Roberts D, Lai	Health System Access and Patient Journey	\$30,000	2021	New-Awarded in 2020

Granting body	Awardees	Project title	Grant total \$	Years	Status
	H, Dietze P,Stoove M.				
NSW Ministry of Health	Cairns R, Buckley NA, Roberts D, Brown J, Adamo G, Wright N	NSW Poisons Information Centre AusVapeSafety study	\$35,400	2021- 2022	New- Awarded in 2020
NSW Ministry of Health	Conigrave K, Conigrave J, Doyle M, Lee K, Dobbins T Morley K. (Als Haber P, Buckley N, Doran C, Wilson	Co-creating Evidence from the Alcohol and other Drugs Outcomes Register (AoDOR)	\$30,000	2021- 2022	New- Awarded in 2020
NHMRC	Schaffer A, Pearson SA, Buckley NA, Falster M, Brieger D, Abrahamowicz M, Daniels B	Disentangling the interrelationship between multimordibity, multimedicine use, and cardiovascular health	\$480,978	2021- 2023	New- Awarded in 2020
NSW Ministry of Health	Dunlop, Roberts, Lintzeris, Haber, Ezard, Maher, McEntyre, White, Doyle, Graham	How does long acting depot buprenorphine impact on the high-risk post- release period for people with opioid dependence – The Release Study	\$798,652	2021- 2023	New- Awarded in 2020
Australian Research Data Commons	Cairns R, Wright N, Elliott R, Wylie C, Lynch AM, Dawson A, Greene S, Isoardi K, Armstrong J, Buckley N, Chiew A, Huynh A, Brown J.	Boosting public health research with a national poisoning dataset	\$525,000	2021- 2023	New- Awarded in 2020
NHMRC	Lee KSK, Wilson S, Conigrave K, Chikritzhs T, Hayman N, Dawson A, Ali R, Conigrave J, Fitts M	Better data on methamphetam ine s and other drugs among Indigenous Australians to	\$2,614,769	2021- 2025	New- Awarded in 2020

Granting body	Awardees	Project title	Grant total \$	Years	Status
		inform policy and practice.			
NHMRC	Fatovich D, Soderstrom J, Dawson A, Alfred S, Greene S, Isorardi K, Pulbrook L, McCutcheon D, Oosthuizen	Emerging Drugs Network of Australia: a coordinated toxicosurveillance system of illicit drug use in Australia to enable rapid detection and harm reduction responses via an Early Warning System	\$3,722,731	2021 - 2023	New-Awarded in 2020
NIH/NIAAA Grant	Seth, D., Morgan, T., Foroud, T., Cordell, H., Daly, A., Whitfield, J., Haber, P.	Genetic risk factors for alcoholic cirrhosis: genome-wide case-control study - Extension	\$163,630	2021	New-Awarded in 2020
NHMRC Ideas Grant.	CIs: Withall, Schofield, Ginnivan, Hwang; Als: Butler, Snoyman, Greenberg, Monds, Radford, Dingwall, Howie, Reutens.	ASCAPE: Audio App-delivered Screening for Cognition and Age-related Health in Older Prisoners.	\$844,050	2021-2023	New-Awarded in 2020
NHMRC	Eastwood, Hiscock, Goldfield, Gillespie, Haber, de Leeuw, Katz, Page, Schneider, Cunich	A Centre of Research Excellence for Integrated Community Care of People with Complex Multi-morbidities	\$3,000,000	2020 - 2025	Existing - Ongoing in 2021
NHMRC	Pearson SA, Pratt N, Buckley N, Preen D, Degenhardt L, Van Gool K, Vajdic C, Jorm L, Wilson A, Henry D	NHMRC Centre of Research Excellence in Medicines Intelligence	\$2,500,000	2020 - 2025	Existing - Ongoing in 2021
NHMRC Ideas Grant.	Askew D, Abbott H, d'Antoine H,	Fetal Alcohol Spectrum Disorder:	\$726,743	2020 - 2023	Existing - Ongoing in 2021

Granting body	Awardees	Project title	Grant total \$	Years	Status
	Poole N, Egert S, Schluter P, Liddle K. (Conigrave K AI)	prevention and coordination of support for urban Aboriginal and Torres Strait Islander people and communities			
Edith Collins Seed Funding	Day, C.	Covid-19 related changes to opiate agonist treatment (COVAT) project	\$25,000	2020-2022	Existing - Ongoing in 2021
NSW Health	Dunlop, Bonevski, Lintzeris, Ezard, Gartner, Jackson, Rich, Oldmeadow, Searles, Nean, Harrod, Haber, Gill, Graham, Hallinan	Harmony study: A trial of the effectiveness of vaporised nicotine products (VNPs) for smoking cessation amongst NSW opiate agonist treatment (OAT) clients	\$950,000	2020 - 2022	Existing - Ongoing in 2021
Edith Collins Seed Funding	Morley KC (CIA)	Harnessing novel technologies to examine mediators of suicidal ideation following admission for self-harm.	\$25,000	2020-2022	Existing - Ongoing in 2021
Edith Collins Seed Funding	Morley KC (CIA)	Reducing recurrent self-poisoning and suicide risk by delivering interventions for substance use disorder by telehealth: The OPTIMISE project.	\$25,000	2020-2022	Existing - Ongoing in 2021
Moyira Elizabeth Vine Fund for research into Schizophrenia	Morley KC (CIA)	A pilot randomised trial of adjunct N acetylcysteine for comorbid schizophrenia and substance use disorder.	\$100,000	2020-2021	Existing - Ongoing in 2021
NHMRC Project Grant	Stapinski L, Newton N, Snijder M, Doyle M, Champion K, Chapman C. (Conigrave K is	Strong and Deadly Futures: A cluster RCT of a computerised school-based alcohol and drug	\$1,907,377	2019-2024	Existing - Ongoing in 2021

Granting body	Awardees	Project title	Grant total \$	Years	Status
	an Associate investigator).	prevention program for Aboriginal and Torres Strait Islander students			
NHMRC	Morley KC (CIG)	The eCLIPSE Project: implementing evidence-based eHealth interventions for comorbid mental health and alcohol/other drug use problems into health and community settings	\$196,973	2019-2023	Existing - Ongoing in 2021
Suicide Prevention Australia	Morley KC (CIC)	Preventing repeated self-poisoning: A brief therapy text message intervention	\$523,614	2019-2022	Existing - Ongoing in 2021
University of Sydney School of Psychology Booster Grant	Van Golde & Monds	The effects of stress on memory for repeated events in emergency workers/first responders	\$10,000	2019-2021	Existing - Ongoing in 2021
UNSW Medicine Neuroscience	Watson, Le Pelley, Prior, Monds, McCraw, Smith, Weirs, & Knock	Cognitive bias modification for enhancing treatment efficacy in alcohol use disorder: pilot study of an adapted protocol aimed at reducing relapse rates	\$39,455.00	2019-2021	Existing - Ongoing in 2021
NHMRC – Project Grant	Chitty, K, Pilgrim J, Cairns R, Schaffer A. (Als: Buckley NA, Pearson SA, Page A, Carter G, Wylie C, Raubenheimer J)	Health service and medicine utilisation before suicide: optimising suicide prevention using population-based linkage of routinely collected data	\$363,856	2019-2021	Existing - Ongoing in 2021

Granting body	Awardees	Project title	Grant total \$	Years	Status
Lambert Initiative for Cannabinoid Research	Haber, Lintzeris, Morley, McGregor	Randomised, controlled trial of cannabidiol (CBD) for the treatment of alcohol withdrawal	\$295,000	2019 - 2021	Existing - Ongoing in 2021
NHMRC/International Collaborations	Dawson, A., Conigrave, K., Buckley, N., Lee, K.	A randomised stepped wedge trial of the scaling up of a community-based alcohol education program in rural Sri Lankan villages	\$813,969	2018-2021	Existing - Ongoing in 2021
NHMRC/ Project Grant	Mills, K., Slade, T., Marel, C., Ross, J., Teesson, M., Haber, P., Darke, S.	Australian Longitudinal Study of Heroin Dependence: An 18-20yr prospective cohort study of mortality, abstinence, and psychiatric and physical health comorbidity	\$1,193,609	2018-2021	Existing - Ongoing in 2021
NHMRC - Project Grant	Degenhardt L, Pearson SA, Dobbins T, Gisev N, Currow D, Blyth F, Larney S, Dunlop A, Mattick R, Wilson A. (Als: Buckley N, Cohen, Coory, Farrell M, Haber P, Ivers R)	Combating escalating harms associated with pharmaceutical opioid use	\$969,205	2018-2021	Existing - Ongoing in 2021
University of Sydney – UNSW Australia Seed Funding Scheme: Mental Health, Drug and Alcohol Comorbidity	Monds, Smith, Lintzeris, Ezard, Bruno, Dobbins	What neurocognitive and mental health factors predict quality of life improvements and treatment outcomes among stimulant users seeking treatment?	\$20,000	2018-2021	Existing - Ongoing in 2021

Granting body	Awardees	Project title	Grant total \$	Years	Status
University of Sydney – UNSW Australia	Morley KC	Evaluation of DDCAT in NSW Drug and Alcohol settings in local health districts and non - government	\$20,000	2018 - 2019	Existing - Ongoing in 2021
NHMRC CRE	K. Conigrave, S. Wilson, A Shakeshaft, N Hayman, P. Haber, K. Lee, R, Ivers, C. Doran, A. Clifford.	A Centre for Research Excellence: Building Indigenous research capacity to find solutions to alcohol problems (NHMRC CRE: APP1117198)	\$2,530,928	2017-2023	Existing - Ongoing in 2021
NHMRC	Isbister GK, Buckley NA, DeSilva HJ, Brown SG, Hodgson W, Lalloo D, de Silva A, Dawson AH, Gawarammana I, Graudins A.	NHMRC Centre of Research Excellence in Translational venom and antivenom research	\$2,500,000.00	2016-2021	Existing - Ongoing in 2021
NHMRC Practitioner Fellowship	Conigrave KM	Working with Indigenous services and communities to reduce the harms from alcohol	\$474,512	2017-2022	Existing - Ongoing in 2021
NHRMRC Project Grant	K. Conigrave, P.Haber, N. Hayman, K. Lee, R. Ivers, T. Dobbins, D. Gray, D. Johnson, S. Wilson.	Increasing uptake of evidence-based management of unhealthy alcohol use in Aboriginal primary health care services	\$2,252,322	2016-2021	Existing - Ongoing in 2021
NSW Ministry Health	Haber PS	Opioid Treatment Accreditation Course (OTAC)	\$650,000	2018-2021	Existing - Ongoing in 2021
NHMRC/MRFF Practitioner Fellowship	Haber PS	Novel treatment for alcohol use disorder	\$417,500	2019-2023	Existing - Ongoing in 2021
NSW Health/ Research Project Support	Grimison, P., Haber, P., Stockler, M., Lintzeris, N.,	RCT evaluating a cannabis extract for secondary prevention of	\$2,792,269	2015-2021	Existing - Ongoing in 2021

Granting body	Awardees	Project title	Grant total \$	Years	Status
	Simes, R., McGregor, I., Olver, I., Allsop, D., Gedye, C., Kirby, A.	chemotherapy- induced nausea and vomiting			
NHMRC/ Project Grant	Ward, J., Ezard, N., Treloar, C., Mcketin, R., Wilkes, E., Dunlop, A., Conigrave, K., Gray, D., Quinn, B., Wand, H.	Novel interventions to address methamphetamin es in Aboriginal communities	\$2,234,452	2016- 2021	Existing - Ongoing in 2021
		Total	\$39,005,044		
		Total new funding	\$11,304,630		

Awards

- Runner Up Award: APSAD 2021 Client experience of depot-buprenorphine two years post implementation- barriers to treatment and challenges of COVID-19 (Sophia Little, PhD candidate)
- Northern Sydney Local Health District Allied Health Researcher of the Year Award, 2021 (Dr. Lauren A. Monds, PhD)
- Nominated for the 2021 NSW Health Excellence in Allied Health Award – Allied Health Researcher / Educator of the Year (Dr. Lauren A. Monds, PhD)
- Franklin Women Carers Award, 2021 (Dr Morley, K.C, PhD)
- Finalist, Australia India Science, Research & Development Award by the India Australia Business Community Awards (IABCA) 2020
- Institute of Precision Medicine & Bioinformatics (IPM&B), Sydney Local Health District: Featured Devanshi Seth's Research Program in IPM&B e-Newsletter on genetics of alcoholic liver disease
- Centenary Award Q2: Publication in high impact factor journal as senior author \$5000 (Schwantes-AN...Seth D, Hepatology 2021)
- Featured article on South Asian women in STEMM by South Asian Australians Representing Ideas (SAARI) <https://saaricollective.com.au/community/blog/powerhouse-south-asian-women-in-stem-in-conversations-with-dr-devanshi-seth-and-dr-onisha-patel/>, 2021 (Dr Seth Devanshi)
- SwitchHub Team Video interview on YouTube and Spotify: Devanshi Seth's journey as woman leader in science and alcohol research <https://www.youtube.com/watch?v=QFm9TEEOSAQ>
- Awarded Senior Scientist Poster Prize Runner-up APSAD 2021 (Dr Sharon Reid, PhD)

Publications

Books & book chapters (n = 16)

1. Assan R, Zheng C, Wilson S, Freeburn B, Boffa J, Purcell-Khodr G, Doyle M, Conigrave K (2021). Specific populations: Aboriginal and Torres Strait Islander Peoples. In PS Haber, BC Riordan (eds.), *Guidelines for the Treatment of Alcohol Problems* (4th edition). Specialty of Addiction Medicine, The University of Sydney; 2021.
2. Baillie A, Pham J, Morley KC, Stapinski L, Mills K, Marel C, Kay-Lambkin F & Teesson M (2021). Comorbidities: Co-Occurring Mental and Alcohol Use Disorders. In Haber PS, Riordan BC (Eds.). *Guidelines for the Treatment of Alcohol Problems* (4th edition). Sydney: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney
3. Day C, White N, Reid S (2021). Gender-Specific Issues. In Haber PS, Riordan BC (Eds.). *Guidelines for the Treatment of Alcohol Problems* (4th edition). Sydney: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney
4. De Jong, C. A., Crockford, D., Welle-Strand, G., Iskandar, S., Sarkar, S., Haber, P. S., & Miller, M. (2021). Pathways to the Specialty Recognition of Addiction Medicine. In *Textbook of Addiction Treatment* (pp. 837-852). Springer, Cham.
5. Haber PS (2021). Aftercare and long-term follow-up. In PS Haber, BC Riordan (eds.), *Guidelines for the Treatment of Alcohol Problems* (4th edition). Specialty of Addiction Medicine, The University of Sydney; 2021.
6. Haber PS (2021). Relapse Prevention, Aftercare, and Long-Term Follow-Up. In Haber PS, Riordan BC (Eds.). *Guidelines for the Treatment of Alcohol Problems* (4th edition). Sydney: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney
7. Haber PS, Lintzeris N (2021). Alcohol Withdrawal. In Haber PS, Riordan BC (Eds.). *Guidelines for the Treatment of Alcohol Problems* (4th edition). Sydney: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney
8. Haber PS, Riordan BC (2021). *Guidelines for the Treatment of Alcohol Problems* (4th edition). Sydney: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney
9. Logge, W., Morley K., Haber P. GABAB receptors and alcohol use disorders: clinical studies. Series title "Current Topics in Behavioral Neurosciences". Volume title: "Behavioral Neurobiology of GABAB Receptor Function". Editors: Styliani Vlachou and Kevin Wickman. Springer, 2020.
10. Monds L, Ridley N, Logge W, Withall A (2021). Specific populations: Cognitive impairment. In PS Haber, BC Riordan (eds.), *Guidelines for the Treatment of Alcohol Problems* (4th edition). Specialty of Addiction Medicine, The University of Sydney; 2021.
11. Mooney-Somers J, Black N, Memedovic S, Lea T, Roxburgh A (2021). Sexuality and Gender Diverse Populations. In Haber PS, Riordan BC (Eds.). *Guidelines for*

the Treatment of Alcohol Problems (4th edition). Sydney: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney

12. Mooney-Sommers J, Black N, Memedovic S, Lea T, Roxburgh A (2021). Specific populations: Sexuality and gender diverse populations. In PS Haber, BC Riordan (eds.), *Guidelines for the Treatment of Alcohol Problems (4th edition)*. Specialty of Addiction Medicine, The University of Sydney; 2021.
13. Morley KC, Rombouts S, Jamshidi N, Haber PS (2021). Pharmacotherapies. In PS Haber, BC Riordan (eds.), *Guidelines for the Treatment of Alcohol Problems (4th edition)*. Specialty of Addiction Medicine, The University of Sydney; 2021.
14. Riordan BC, Cunningham J, Kay-Lambkin F (2021). Brief e-Health Interventions for Alcohol Use and Related-Problems. In Haber PS, Riordan BC (Eds.). *Guidelines for the Treatment of Alcohol Problems (4th edition)*. Sydney: Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney
15. Riordan BC, Haber PS (2021). An Introduction to the Guidelines for the Treatment of Alcohol Problems. In PS Haber, BC Riordan (eds.), *Guidelines for the Treatment of Alcohol Problems (4th edition)*. Specialty of Addiction Medicine, The University of Sydney; 2021.
16. Riordan BC, Winter DT, Haber PS (2021). Prevalence of alcohol consumption and related harms in Australia. In PS Haber, BC Riordan (eds.), *Guidelines for the Treatment of Alcohol Problems (4th edition)*. Specialty of Addiction Medicine, The University of Sydney; 2021.

Journals articles (n = 120)

1. Ackermann D, Blyth F, Burgess A, Reid S. Rapid Evidence for Practice modules: using team-based learning to teach evidence-based medicine, *International Journal of Epidemiology*, Volume 50, Issue Supplement_1, September 2021, dyab168.008, <https://doi.org/10.1093/ije/dyab168.008>
2. Al Ansari, M., Dawson, A., & Conigrave, K. (2021). Alcohol: from Mesopotamia to Modern Iraq. *J Ethn Subst Abuse*, 20(3), 343-365. doi:10.1080/15332640.2019.1657541
3. Al-Alansari, F., et al. (2021). "Health risks, preventive behaviours and respiratory illnesses at the 2019 Arbaeen: Implications for COVID-19 and other pandemics " *Environmental Research and Public Health* 18(6).
4. Baillie, A., Marel, C., Mills, K., Morley, K., Teesson, M. (2021). Treatment for comorbidity. *Guidelines For The Treatment of Alcohol Problems*, Australian Government Department for Health and Aging, Chapter 10. <https://alcoholtreatmentguidelines.com.au>
5. Barnett, A., Savic, M., Lintzeris, N., Bathish, R., Arunogiri, S., Dunlop, A. J., . . . Lubman, D. I. (2021). Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. *Drug Alcohol Depend*, 227, 108959. doi:10.1016/j.drugalcdep.2021.108959

6. Best, D., et al. (2021). "Justice Capital: A model for reconciling structural and agentic determinants of desistance." *Probation Journal* 68(2).
7. Brett, J., Pearson, S. A., Daniels, B., Wylie, C. E., & Buckley, N. A. (2021). A cross sectional study of psychotropic medicine use in Australia in 2018: A focus on polypharmacy. *Br J Clin Pharmacol*, 87(3), 1369-1377. doi:10.1111/bcp.14527
8. Bryant, J., et al. (2021). "Beyond deficit: 'strengths-based approaches' in Indigenous health research." *Sociology of Health & Fitness*.
9. Buckley, N. A., Fahim, M., Raubenheimer, J., Gawarammana, I. B., Eddleston, M., Roberts, M. S., & Dawson, A. H. (2021). Case fatality of agricultural pesticides after self-poisoning in Sri Lanka: a prospective cohort study. *Lancet Glob Health*, 9(6), e854-e862. doi:10.1016/s2214-109x(21)00086-3
10. Chakraborty S, Jones M, Collie A, Kenardy J, Mortimer D, Brijnath B, Enticott J, Kidd M, Trevena L, Reid S, and Mazza D. Implementing work-related Mental health guidelines in general practice (IMPRovE): a protocol for a hybrid-III parallel cluster randomised controlled trial. *Implementation Science* 2021.16:77
11. Chan, B. S., & Buckley, N. A. (2021). Authors' reply to comment on: clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. *Clin Toxicol (Phila)*, 1. doi:10.1080/15563650.2021.2013497
12. Chan, B. S., & Buckley, N. A. (2021). Translating EXTRIP criteria to better define patients with lithium toxicity for haemodialysis. *Br J Clin Pharmacol*, 87(4), 2157. doi:10.1111/bcp.14567
13. Chan, B. S., Isbister, G. K., Chiew, A., Isoardi, K., & Buckley, N. A. (2021). Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6). *Clin Toxicol (Phila)*, 1-7. doi:10.1080/15563650.2021.1968422
14. Chan, B. S., Kiss, A., McIntosh, N., Sheppeard, V., & Dawson, A. H. (2021). E-cigarette or vaping product use-associated lung injury in an adolescent. *Med J Aust*, 215(7), 313-314.e311. doi:10.5694/mja2.51244
15. Chiew, A. L., & Buckley, N. A. (2021). Acetaminophen Poisoning. *Crit Care Clin*, 37(3), 543-561. doi:10.1016/j.ccc.2021.03.005
16. Chiew, A. L., Buckley, N. A., Graudins, A., & Munir, V. L. (2021). Review article: Up (to) date for Australian Toxicology and Toxinology guidelines. *Emerg Med Australas*, 33(1), 6-8. doi:10.1111/1742-6723.13663
17. Chitty, K. M., Schumann, J. L., Moran, L. L., Chong, D. G., Hurzeler, T. P., & Buckley, N. A. (2021). Reporting of alcohol as a contributor to death in Australian national suicide statistics and its relationship to post-mortem alcohol concentrations. *Addiction*, 116(3), 506-513. doi:10.1111/add.15180
18. Clapham, K., et al. (2021). "Digital support for Indigenous research methodologies" *Australasian Journal of Information Systems* 25.
19. Conigrave, J. H., et al. (2021). "Alcohol consumption and dependence is linked to the extent that people experience need satisfaction while drinking alcohol in two Aboriginal and Torres Strait Islander communities." *Addiction Science & Clinical Practise* 16(1): 1-11.

20. Conigrave, J. H., Conigrave, K. M., Wilson, S., & Lee, K. S. K. (2021). Indigenous Australian drinking risk: Comparing risk categorisations based on recall of recent drinking occasions to AUDIT-C screening in a representative sample. *Drug Alcohol Rev.* doi:10.1111/dar.13403
21. Conigrave, J. H., Harrison, K. H., Lee, K. S. K., Dobbins, T. A., Hummerston, B., Hayman, N., . . . Conigrave, K. M. (2021). Support can increase use of the AUDIT-C in Australian Aboriginal Community Controlled Health Services: a cluster randomized trial. *Addiction*, 116(9), 2304-2315. doi:10.1111/add.15428
22. Conigrave, K. M., Ali, R. L., Armstrong, R., Chikritzhs, T. N., d'Abbs, P., Harris, M. F., . . . Banks, E. (2021). Revision of the Australian guidelines to reduce health risks from drinking alcohol. *Med J Aust*, 215(11), 518-524. doi:10.5694/mja2.51336
23. Coupland, H., Day, C., Haber, P., Pritchard-Jones, J., McKee, K., George, J., & McCaughan, G. (2021). Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. *Drug Alcohol Rev.* doi:10.1111/dar.13414
24. Coupland, H., Moensted, M. L., Reid, S., White, B., Eastwood, J., Haber, P., & Day, C. (2021). Developing a model of care for substance use in pregnancy and parenting services, Sydney, Australia: Service provider perspectives. *J Subst Abuse Treat*, 131, 108420. doi:10.1016/j.jsat.2021.108420
25. Crouse, J. J., Morley, K. C., Buckley, N., Dawson, A., Seth, D., Monds, L. A., Tickell, A., Kay-Lambkin, F., Chitty, K. M. (2021). Online interventions for people hospitalized for deliberate self-harm and problematic alcohol use: Lessons learned from the iiAIM trial. *Bull Menninger Clin*, 85(2), 123-142. doi:10.1521/bumc.2021.85.2.123
26. Dale, E., Conigrave, K. M., Kelly, P. J., Ivers, R., Clapham, K., & Lee, K. S. K. (2021). A Delphi yarn: applying Indigenous knowledges to enhance the cultural utility of SMART Recovery Australia. *Addict Sci Clin Pract*, 16(1), 2. doi:10.1186/s13722-020-00212-8
27. Dale, E., Lee, K. S. K., Conigrave, K. M., Conigrave, J. H., Ivers, R., Clapham, K., & Kelly, P. J. (2021). A multi-methods yarn about SMART Recovery: First insights from Australian Aboriginal facilitators and group members. *Drug Alcohol Rev*, 40(6), 1013-1027. doi:10.1111/dar.13264
28. Daniels, B., Pearson, S. A., Buckley, N. A., Bruno, C., Schaffer, A., & Zoega, H. (2021). Coming to grips with seemingly conflicting results in programme evaluation: the devil's in the detail. *BMJ Qual Saf*, 30(1), 70-71. doi:10.1136/bmjqs-2020-012118
29. Dassanayake, T. L., Weerasinghe, V. S., Gawarammana, I. B., & Buckley, N. A. (2021). Changes of attention-related brain activity over 6 months after acute organophosphate pesticide poisoning: a prospective follow-up study. *Clin Toxicol (Phila)*, 1-9. doi:10.1080/15563650.2021.2010742
30. Day, C. A., et al. (2021). "Providing appropriate treatment and care to people with alcohol problems: a summary for key specific populations" *Medical Journal of Australia* 215: S21-S27.

31. Donald, J. N., et al. (2021). "Paths to the light and dark sides of human nature: A meta-analytic review of prosocial benefits of autonomy and the antisocial costs of control " *Psychological Bulletin* 147(9): 921-946.
32. Doyle, M. F. (2021). Alcohol and drug research with Indigenous peoples: where do we go from here? *Addiction*, 116(3), 435-437. doi:10.1111/add.15176
33. Doyle, M. F., Williams, M., Butler, T., Shakeshaft, A., Conigrave, K., & Guthrie, J. (2021). Perspectives of prisoners on alcohol and other drug group treatment approaches. *Int J Prison Health*, ahead-of-print(ahead-of-print). doi:10.1108/ijph-05-2021-0043
34. Dunlop, A. J., White, B., Roberts, J., Cretikos, M., Attalla, D., Ling, R., ... & Lintzeris, N. (2022). Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings. *Addiction*, 117(2), 382-391.
35. Dzikowska, M., et al. (2021). "Support for Aboriginal health services in reducing harms from alcohol: 2-year service provision outcomes in a cluster randomized trial." *Addiction* 117(3).
36. Ediriweera, D. S., Kasthuriratne, A., Pathmeswaran, A., Gunawardene, N. K., Jayamanne, S. F., Murray, K., . . . Diggle, P. J. (2021). Evaluating spatiotemporal dynamics of snakebite in Sri Lanka: Monthly incidence mapping from a national representative survey sample. *PLoS Negl Trop Dis*, 15(6), e0009447. doi:10.1371/journal.pntd.0009447
37. Falster, M. O., Charrier, R., Pearson, S. A., Buckley, N. A., & Daniels, B. (2021). Long-term trajectories of medicine use among older adults experiencing polypharmacy in Australia. *Br J Clin Pharmacol*, 87(3), 1264-1274. doi:10.1111/bcp.14504
38. Farhoudian, A., Radfar, S. R., Mohaddes Ardabili, H., Rafei, P., Ebrahimi, M., Khojasteh Zonoozi, A., . . . Ekhtiari, H. (2021). A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic. *Front Psychiatry*, 12, 646206. doi:10.3389/fpsyt.2021.646206
39. Fernando, Kiyara; Jayamanna, Shaluka; Weerasinghe, Manjula; Priyadarshana, Chamil; Ratnayake, Rohan; Pearson, Melissa; Gunnell, David; Dawson, Andrew; Hawton, Keith; Konradsen, Flemming; Risk factors for deliberate self-harm in young people in rural Sri Lanka: a prospective cohort study of 22,000 individuals.
40. Fitts, M. S., Burchill, R., Wilson, S., Palk, G. R., Clough, A. R., Conigrave, K. M., . . . Lee, K. S. K. (2021). Drink driving among Aboriginal and Torres Strait Islander Australians: What has been done and where to next? *Drug Alcohol Rev*. doi:10.1111/dar.13418
41. Forbes MK, Sunderland M, Rapee RM, et al. A Detailed Hierarchical Model of Psychopathology: From Individual Symptoms up to the General Factor of Psychopathology. *Clinical Psychological Science*. 2021;9(2):139-168. doi:10.1177/2167702620954799
42. Freeburn, B., et al. (2021). "Coming of age: 21 years of opioid substitution treatment within an Aboriginal community-controlled primary health service." *Drug and Alcohol Review*.

43. Giannopoulos, V., Morley, K., Uribe, G., Louie, E., Wood, K., Teesson, M., Baillie, A., Haber, P. (2021). The role of clinical supervision in implementing evidence-based practice for managing comorbidity. *The Clinical Supervisor*, 40(10), 158-177
44. Giannopolous, V., Morley, K, Haber, P (2021). How GPs can help detect and manage alcohol problems during the COVID-19 pandemic? *Medicine Today* 22 (4): 14-20
45. Haber, P. S., & Kortt, N. C. (2021). Alcohol use disorder and the gut. *Addiction*, 116(3), 658-667. doi:10.1111/add.15147
46. Haber, P. S., Morley, K. C., & Giannopoulos, V. (2021). Alcohol-use and misuse during the COVID-19 pandemic.
47. Haber, P. S., Riordan, B. C., & Morley, K. C. (2021). Treatment of alcohol problems: current status and future directions. *Med J Aust*, 215(7), 315-316. doi:10.5694/mja2.51265
48. Haber, P. S., Riordan, B. C., Winter, D. T., Barrett, L., Saunders, J., Hides, L., ... & Morley, K. C. (2021). New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. *Medical Journal of Australia*, 215, S3-S32.
49. Haber, P.S., Riordan, B.C., Winter, D.T., Barrett, L., Saunders, J., Hides, L., Gullo, M., Manning, V., Day, C.A., Bonomo, Y. and Burns, L., 2021. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. *Medical Journal of Australia*, 215, pp.S3-S32.
50. Hamilton, S. L. and S. Maslen (2021). "Redressing 'unwinnable battles': Towards institutional justice capital in Australian child protection." *Journal of Sociology*: 14407833211010220
51. Hamilton, S. L., et al. (2021). "'We don't want you to come in and make a decision for us': Traversing cultural authority and responsive regulation in Australian child protection systems." *Australian Journal of Social Issues*.
52. L Hides, BC Riordan, M Gullo, KC Morley, V Manning, J Connor, C Quinn. Caring for and managing patients with alcohol problems: interventions, treatments, relapse prevention, aftercare, and long term follow-up. *Medical Journal of Australia*, 215 (7): S12-S20
53. Huang, J., Buckley, N. A., Isoardi, K. Z., Chiew, A. L., Isbister, G. K., Cairns, R., . . . Chan, B. S. (2021). Angiotensin axis antagonists increase the incidence of haemodynamic instability in dihydropyridine calcium channel blocker poisoning. *Clin Toxicol (Phila)*, 59(6), 464-471. doi:10.1080/15563650.2020.1826504
54. Hurzeler, T., Buckley, N. A., Noghrehchi, F., Malouf, P., Page, A., Schumann, J. L., & Chitty, K. M. (2021). Alcohol-related suicide across Australia: a geospatial analysis. *Aust N Z J Public Health*, 45(4), 394-399. doi:10.1111/1753-6405.13122
55. Hurzeler, T., Giannopoulos, V., Uribe, G., Louie, E., Haber, P., & Morley, K. C. (2021). Psychosocial Interventions for Reducing Suicidal Behaviour and Alcohol Consumption in Patients With Alcohol Problems: A Systematic Review of

Randomized Controlled Trials. *Alcohol Alcohol*, 56(1), 17-27.
doi:10.1093/alcalc/agaa094

56. James, D. B., Lee, K. S. K., Dronavalli, M., Courtney, R. J., Conigrave, K. M., Conigrave, J. H., & Shakeshaft, A. (2021). Predictors of length of treatment, discharge reason, and re-admission to Aboriginal alcohol and other drug residential rehabilitation services in New South Wales, Australia. *Drug Alcohol Rev*. doi:10.1111/dar.13388
57. Jiang, E., Raubenheimer, J. E., Isbister, G. K., Chan, B. S. H., & Buckley, N. A. (2021). Machine read frontal QRS-T angle and QTc is no substitute for manual measurement of QTc in pro-arrhythmic drug overdose. *J Electrocardiol*, 65, 151-156. doi:10.1016/j.jelectrocard.2021.02.006
58. Jiranantakan, Thanjira; Brown, Jared A; Auld, Robin; Francis, Catherine; Vazquez, Santiago; Shaw, Vanessa; Mcdonald, Catherine; Wright, Nicole E; Dawson, Andrew; Surprise Illicit Substances-Lessons Learned From The Prescription, Recreational And Illicit Substance Evaluation Program In New South Wales. *Drug and Alcohol Review*. 40S31-S32. 2021
59. Kloft, L., Monds, L.A., Blokland, A., Ramaekers, J., & Otgaar, H. (2021). Hazy memories in the courtroom: a review of alcohol and other drug effects on false memory and suggestibility. *Neuroscience and Biobehavioral Reviews*, 124, 291-307
60. Kaye, S., Lewandowski, A., Bowman, J., & Doyle, M. F. (2021). Crystal methamphetamine use among young people entering custody: Prevalence, correlates and comorbidity. *Drug Alcohol Rev*, 40(7), 1266-1274. doi:10.1111/dar.13210
61. Lee, K. K., Conigrave, J. H., Al Ansari, M., Wilson, S., Perry, J., Zheng, C., et al., Conigrave, K. M. (2021). Acceptability and feasibility of a computer-based application to help Aboriginal and Torres Strait Islander Australians describe their alcohol consumption. *J Ethn Subst Abuse*, 20(1), 16-33. doi:10.1080/15332640.2019.1579144
62. Lintzeris, N., Dunlop, A. J., Haber, P. S., Lubman, D. I., Graham, R., Hutchinson, S., et al., Tiberg, F. (2021). Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. *JAMA Netw Open*, 4(5), e219041. doi:10.1001/jamanetworkopen.2021.9041
63. Logge WB, Morley KC, Haber PS. GABAB receptors and alcohol use disorders: clinical studies. *Behavioral Neurobiology of GABAB Receptor Function*. 2021 Feb 13:195-212.
64. Logge, W. B., Morris, R. W., Baillie, A. J., Haber, P. S., & Morley, K. C. (2021). Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. *Psychopharmacology (Berl)*, 238(5), 1291-1302. doi:10.1007/s00213-019-05192-5
65. Louie, E., Barrett, E. L., Baillie, A., Haber, P., & Morley, K. C. (2021). A systematic review of evidence-based practice implementation in drug and alcohol settings: applying the consolidated framework for implementation research framework. *Implement Sci*, 16(1), 22. doi:10.1186/s13012-021-01090-7

66. Louie, E., Giannopoulos, V., Baillie, A.J., Uribe, G., Wood, K., Teesson, M., Childs, S., Rogers, D., Haber, P.S., & Morley, K.C. (2021). Barriers and Facilitators to the Implementation of the Pathways to Comorbidity Care (PCC) Training Package for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings. *Frontiers in Health Services*.
67. Louie, E., Morley, K. C., Giannopoulos, V., Uribe, G., Wood, K., Marel, C., et al., Haber, P. S. (2021). Implementation of a Multi-Modal Training Program for the Management of Comorbid Mental Disorders in Drug and Alcohol Settings: Pathways to Comorbidity Care (PCC). *J Dual Diagn*, 17(4), 304-312. doi:10.1080/15504263.2021.1984152
68. Marel, C., Mills, K., Stirling, R., Wilson, J., Haber, P., Teesson, M. (2021). Editorial. *Advances in Dual Diagnosis*, 14(1), 1-7
69. Mason, A., Jang, K., Morley, K., Scarf, D., Collings, S. C., & Riordan, B. C. (2021). A Content Analysis of Reddit Users' Perspectives on Reasons for Not Following Through with a Suicide Attempt. *Cyberpsychol Behav Soc Netw*, 24(10), 642-647. doi:10.1089/cyber.2020.0521
70. Mazza, D., Chakraborty, S., Camões-Costa, V., Kenardy, J., Brijnath, B., Mortimer, D., et al., Collie, A. (2021). Implementing work-related mental health guidelines in general PRactice (IMPRovE): a protocol for a hybrid III parallel cluster randomised controlled trial. *Implementation Science*, 16(1), 77. doi:10.1186/s13012-021-01146-8
71. M McDonough, AJ Baillie, PJ Clark, L Gowing, LA Stapinski, B Taye, Morley, K.C. Caring for and managing patients with alcohol problems: interventions, treatments, relapse prevention, aftercare, and long term follow-up. *Medical Journal of Australia*, 215 (7): S28-S32
72. Moensted ML & Buus N, Day CA. Examining facilitating relational dimensions of service encounters for disadvantaged people who use drugs. *Journal of Addictions Nursing*. (accepted 04/03/2021)
73. Moensted ML Day CA. (2021) Operationalising cultural competency in the context of substance use treatment for Australian Muslims: A qualitative analysis. *Drugs: Education, Prevention & Policy*. doi.org/10.1080/09687637.2021.1872501
74. Monds, L. A., Riordan, B. C., Flett, J. A. M., Conner, T. S., Haber, P., & Scarf, D. (2021). How intoxicated are you? Investigating self and observer intoxication ratings in relation to blood alcohol concentration. *Drug Alcohol Rev*, 40(7), 1173-1177. doi:10.1111/dar.13241
75. Morley, K. C. (2021). Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact. *Addiction*, 116(11), 3027-3028. doi:10.1111/add.15532
76. Morley, K. C., Logge, W. B., Fraser, I., Morris, R. W., Baillie, A. J., & Haber, P. S. (2021). High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study. *Eur Neuropsychopharmacol*, 46, 28-36. doi:10.1016/j.euroneuro.2021.02.010

77. Morley, K. C., Logge, W. B., Riordan, B. C., Brannon, S., Haber, P. S., & Conner, T. S. (2021). Daily experiences of hangover severity and food consumption in young adults. *Br J Health Psychol.* doi:10.1111/bjhp.12555
78. Morley, K. C., Perry, C. J., Watt, J., Hurzeler, T., Leggio, L., Lawrence, A. J., & Haber, P. (2021). New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies. *Expert Opin Pharmacother*, 22(10), 1291-1303. doi:10.1080/14656566.2021.1892641
79. Morley, K.C. Rombouts, S. Jamshidi, N., Haber, P.S. (2021). Pharmacotherapies for alcohol dependence. *Guidelines For The Treatment of Alcohol Problems*, Australian Government Department for Health, Chapter 7. <https://alcoholtreatmentguidelines.com.au/>
80. Nielsen, S., Sanfilippo, P., Belackova, V., Day, C., Silins, E., Lintzeris, N., et al., Larance, B. (2021). Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. *Addiction*, 116(6), 1482-1494. doi:10.1111/add.15297
81. Noroozi, A., et al. (2021). "Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran " *Drug and Alcohol Review* 41 (2).
82. O'Neill, C., Najjar, Z., Ingleton, A., Edwards, A., Dawson, A., & Gupta, L. (2021). Methaemoglobinaemia associated with the atypical use of sodium nitrite as a food additive. *Med J Aust*, 215(6), 256-257.e251. doi:10.5694/mja2.51233
83. Osna, N. A., Ganesan, M., Seth, D., Wyatt, T. A., Kidambi, S., & Kharbanda, K. K. (2021). Second hits exacerbate alcohol-related organ damage: an update. *Alcohol Alcohol*, 56(1), 8-16. doi:10.1093/alcalc/agaa085
84. Perananthan, V., Mohamed, F., Shahmy, S., Gawarammana, I., Dawson, A., & Buckley, N. (2021). The clinical toxicity of imidacloprid self-poisoning following the introduction of newer formulations. *Clin Toxicol (Phila)*, 59(4), 347-350. doi:10.1080/15563650.2020.1815760
85. Perananthan, V., Tremonti, C., Nash, E., Jiranantakan, T., & Dawson, A. H. (2021). Rapid detection, toxicosurveillance and public health response to stimulant adulteration with acetyl fentanyl. *Med J Aust*, 214(11), 533-533.e531. doi:10.5694/mja2.51112
86. Prasadi, GAM; Senarathna, L; Dharmaratne, SD; Mohamed, F; Jayasinghe, SS; Dawson, A; Mothers' ability to determine and measure paracetamol doses for children—a contrived observational study. *Journal of Child Health Care* 1.36749E+16 2021
87. Prior, K., Salemink, E., Wiers, R. W., Teachman, B. A., Piggott, M., Newton, N. C., et al., Stapinski, L. A. (2021). A Web-Based Cognitive Bias Modification Intervention (Re-train Your Brain) for Emerging Adults With Co-occurring Social Anxiety and Hazardous Alcohol Use: Protocol for a Multiarm Randomized Controlled Pilot Trial. 10(7), e28667. doi:10.2196/28667
88. Pushpakumara, P., Dawson, A., Adikari, A., Thennakoon, S., Abeysinghe, R., Rajapakse, T. (2021). Exploration of associations between deliberate self-

poisoning and psychiatric disorders in rural Sri Lanka: A case-control study. *PLoS one*, 16(8), e0255805

89. Radfar, S. R., De Jong, C. A. J., Farhoudian, A., Ebrahimi, M., Rafei, P., Vahidi, M., et al., Baldacchino, A. M. (2021). Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey. *Front Psychiatry*, 12, 639393. doi:10.3389/fpsy.2021.639393
90. Raubenheimer, J. E., Riordan, B. C., Merrill, J. E., Winter, T., Ward, R. M., Scarf, D., & Buckley, N. A. (2021). Hey Google! will New Zealand vote to legalise cannabis? Using Google Trends data to predict the outcome of the 2020 New Zealand cannabis referendum. *Int J Drug Policy*, 90, 103083. doi:10.1016/j.drugpo.2020.103083
91. Riordan, B. C., Winter, D. T., Haber, P. S., Day, C. A., & Morley, K. C. (2021). What are people saying on social networking sites about the Australian alcohol consumption guidelines? *Med J Aust*, 214(3), 105-107.e101. doi:10.5694/mja2.50902
92. Roberts, D. M., Hughes, H. K., Haber, P. S., & Jones, G. R. (2021). Variability in insulin pharmacokinetics following high-dose insulin therapy. *Clinical Toxicology*, 1-3.
93. Roberts, J., White, B., Attalla, D., Ward, S., & Dunlop, A. J. (2021). Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia. *Addiction*, 116(2), 426-427. doi:10.1111/add.15244
94. Roxburgh, A., Jauncey, M., Day, C., Bartlett, M., Cogger, S., Dietze, P., et al., Clark, N. (2021). Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia. *Harm Reduct J*, 18(1), 20. doi:10.1186/s12954-021-00471-x
95. Schaffer, A. L., Brett, J., Buckley, N. A., & Pearson, S. A. (2021). Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use. *Pain*. doi:10.1097/j.pain.0000000000002433
96. Schwantes-An, T. H., Darlay, R., Mathurin, P., Masson, S., Liangpunsakul, S., Mueller, S., et al., Seth, D. (2021). Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. *Hepatology*, 73(5), 1920-1931. doi:10.1002/hep.31535
97. Seifert, S. A., Buckley, N., Chan, B., Chan, T. Y. K., Cumpston, K., Kirschner, R. I., et al., Wilks, M. F. (2021). Clinical Toxicology review metrics and expert reviewers, 2020. *Clin Toxicol (Phila)*, 59(3), e1-e3. doi:10.1080/15563650.2021.1874197
98. Shihana, F., Barron, M. L., Mohamed, F., Seth, D., & Buckley, N. A. (2021). MicroRNAs in toxic acute kidney injury: Systematic scoping review of the current status. *Pharmacol Res Perspect*, 9(2), e00695. doi:10.1002/prp2.695
99. Shihana, F., Wong, W. K. M., Joglekar, M. V., Mohamed, F., Gawarammana, I. B., Isbister, G. K., Hardikar AA, Seth D, Buckley, N. A. (2021). Urinary microRNAs as non-invasive biomarkers for toxic acute kidney injury in humans. *Sci Rep*, 11(1), 9165. doi:10.1038/s41598-021-87918-0

100. Siefried, K. J., Ezard, N., Christmass, M., Haber, P., Ali, R., & NCCRED Methamphetamine and Emerging Drugs Clinical Research Network Working Group. (2022). A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia. *Drug and Alcohol Review*, 41(2), 309-319.
101. Snijder, M., et al. (2021). "Strong and Deadly Futures: Co-Development of a Web-Based Wellbeing and Substance Use Prevention Program for Aboriginal and Torres Strait Islander and Non-Aboriginal Adolescents." *International journal of environmental research and public health* 18(4): 2176.
102. Stapinski, L. A., Sannibale, C., Subotic, M., Rapee, R. M., Teesson, M., Haber, P. S., & Baillie, A. J. (2021). Randomised controlled trial of integrated cognitive behavioural treatment and motivational enhancement for comorbid social anxiety and alcohol use disorders. *Aust N Z J Psychiatry*, 55(2), 207-220. doi:10.1177/0004867420952539
103. Stearne, A. E., et al. (2021). "Identifying how the principles of self-determination could be applied to create effective alcohol policy for First Nations Australians: Synthesising the lessons from the development of general public policy." *International Journal of Drug Policy*: 103260.
104. Subotic-Kerry, M., Baillie, A., Stapinski, L., Abbott, M., MacDonald, J., Gaston, J., Rapee, R. (2021). The impact of alcohol use disorders and alcohol consumption on treatment-seeking individuals with social anxiety disorder. *Bulletin of the Menninger Clinic*, 85(2), 100-122.
105. Sullivan, A., Ridley, N., Monds, L. A., Logge, W., Hurzeler, T., & Morley, K. (2021). Neuropsychological profiles on the Weschler Adult Intelligence Scale (WAIS-IV) of individuals attending a long-term residential rehabilitation program for substance use problems. *Applied Neuropsychology: Adult*; and Preprinted in PsyArXiv. <https://doi.org/10.31234/osf.io/87rd5>
106. Sunderland, M., Forbes, M., Mewton, L., Baillie, A., Carragher, N., Lynch, S., Batterham, P., Calear, A., Chapman, C., Newton, N., Teesson, M., Slade, T. (2021). The structure of psychopathology and association with poor sleep, self-harm, suicidality, risky sexual behavior, and low self-esteem in a population sample of adolescents. *Development and Psychopathology*, 33(4), 1208-1219.
107. Suntai, Z., & White, B. (2021). Social isolation among older veterans: findings from the National Health and Aging Trends Study. *Aging Ment Health*, 1-8. doi:10.1080/13607863.2021.1942434
108. Tong, A., Sorrell, T., Black, A., Caillaud, C., Chrzanowski, W., Li, E., Martinez-Martin, D., McEwan, A., Wang, R., Motion, A., Casas Bedoya, A., Huang, J., Azizi, L., Eggleton, B., Andersen, T., Baillie, A., Barratt, A., Boehm, C., Britton, P., Chadban, S., Chow, C., Fleming, S., Fox, G., Gordon, L., Ho-Baillie, A., Howell, M., Hickie, I., Hunt, N., Iredell, J., Jin, C., Kairaitis, K., Kavehei, O., Kritharides, L., Leon-Saval, S., Lindley, R., Maguire, S., McCluskey, M., McKay, N., Mifsud, G., Palomba, S., Pettigrew, A., Postnova, S., Prinable, J., Rabeau, J., Rees, M., Richmond, K., Scholes Robertson, N., Seppelt, I., Shaw, T., Sintchenko, V., Snelling, T., Teixeira-Pinto, A., Tovey, E., Tuniz, A., Varamini, P., Wang, A.,

- Wang, K., Wise, S., Zoellner, H., et al (2021). Research priorities for COVID-19 sensor technology. *Nature Biotechnology*, 39(2), 144-153
109. Tran, V., Reid, S. E., Roxburgh, A., & Day, C. A. (2021). Assessing Drug Consumption Rooms and Longer Term (5 Year) Impacts on Community and Clients. *Risk Manag Healthc Policy*, 14, 4639-4647. doi:10.2147/rmhpc.S244720
110. Vichitkunakorn, P., Conigrave, K. M., Geater, A. F., & Assanangkornchai, S. (2021). A Context-Specific Instrument to Record Drinking Behaviour: A Pilot Study on Implications of Identifying the Context of Risky Drinking. *Community Ment Health J*, 57(1), 167-177. doi:10.1007/s10597-020-00629-0
111. Watt J, Haber P, Conigrave K. Managing unhealthy alcohol use in general practice. *Australian Doctor*. 2022;4 March 2022:13-20
112. Weatherall, T. J., et al. (2021). "Prevalence and correlates of alcohol dependence in an Australian Aboriginal and Torres Strait Islander representative sample: Using the Grog Survey App." *Drug and Alcohol Review*.
113. Weatherall, T. J., et al. (2021). "Alcohol dependence in a community sample of Aboriginal and Torres Strait Islander Australians: harms, getting help and awareness of local treatments." *Addiction Science & Clinical Practise* **16**(1): 1-11.
114. Whitfield, J. B., Masson, S., Liangpunsakul, S., Mueller, S., Aithal, G. P., Eyer, F., et al., Seth, D. (2021). Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. *Am J Gastroenterol*, 116(1), 106-115. doi:10.14309/ajg.0000000000000833
115. Whitfield, J. B., Schwantes-An, T. H., Darlay, R., Aithal, G. P., Atkinson, S. R., Bataller, R., et al., & GenomALC Consortium. (2022). A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. *Journal of hepatology*, 76(2), 275-282.
116. Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet JM, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trépo E, Morgan TR, Seth D; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. *J Hepatol*. 2022 Feb;76(2):275-282. doi: 10.1016/j.jhep.2021.10.005. Epub 2021 Oct 14. Erratum in: *J Hepatol*. 2022 Mar 11;; PMID: 34656649; PMCID: PMC8803006.
117. Wijewickrama, E. S., Mohamed, F., Gawarammana, I. B., Endre, Z. H., Buckley, N. A., & Isbister, G. K. (2021). Serum and urinary biomarkers for early detection of acute kidney injury following Hypnale spp. envenoming. *PLoS Negl Trop Dis*, 15(12), e0010011. doi:10.1371/journal.pntd.0010011
118. Winter, D. T., Geiger, B., Morley, K., Conigrave, J., Haber, P. S., & Riordan, B. C. (2021). Are bottle shops using Twitter to increase advertising or encourage drinking during COVID-19? *Aust N Z J Public Health*, 45(4), 391-393. doi:10.1111/1753-6405.13118

119. Winter, D. T., White, N., Geiger, B., Haber, P. S., & Day, C. A. (2021). Should we be using e-vouchers to compensate research participants? Acceptability among opioid agonist treatment clients. *Drug Alcohol Rev*, 40(7), 1356-1357. doi:10.1111/dar.13287
120. Zheng, C., et al. (2021). "Patterns of drinking in Aboriginal and Torres Strait Islander peoples as self-reported on the Grog Survey App: A representative urban and remote sample." *Drug and Alcohol Review*.

Presentations/media (n = 52)

1. Ackerman D, Blyth F, Burgess A, Reid S 2021. Rapid Evidence for Practice modules: using team-based learning to teach evidence-based medicine. World Congress of Epidemiology 3-6 September 2021.
2. Lynette Bullen & Annalee Stearne. (2021). Alcohol policy: compulsory treatment, Aboriginal leadership. Centre of Research Excellence: Indigenous Health and Alcohol. Camperdown/Virtual. 28 October
3. Chakraborty S, Jones M, Collie A, Kenardy J, Mortimer D, Brijnath B, Enticott J, Kidd M, Trevena L, Reid S, and Mazza D. Implementing work-related Mental health guidelines in general practice (IMPRovE): Protocol for a parallel cluster-randomised controlled trial. Evidence and Implementation Summit March 30-31 2021
4. Chakraborty S, Reid S, Rowe C, Camões-Costa V, Raymond J, Carvalho-Silva A, Dinh A, Mortimer D, Enticott J, Collie A, Kenardy J, Brijnath B, Trevena L, Kidd M, Mazza D. Challenges and implications of conducting a complex GP trial during a pandemic: a case study. Australian Association of Academic Primary Care 2021 Annual Research Conference 12-13 August 2021
5. James Conigrave, Kristie Harrison, K.S. Kylie Lee, Tim Dobbins, Beth Hummerston, Noel Hayman, Jimmy Perry, Rowena Iver, Paul Haber, Scott Wilson, David Johnson, Kate Conigrave. Supporting Aboriginal Community Controlled Health Services in screening and alcohol care
6. Kate Conigrave, Peter Jack, Scott Wilson. (2021). Supporting Aboriginal community controlled health services around alcohol care. National Indigenous Drug and Alcohol Conference (NIDAC). Glenelg. 23 - 26 March
7. Kate Conigrave & Scott Wilson. (2021). Supporting Aboriginal community controlled health services around alcohol care. Australasian Professional Society on Alcohol and Drugs. Brisbane /Virtual. 7 - 10 November
8. Coupland H, Henderson C, Pritchard-Jones, J, Kao, S-C, Sheils, S, Nagy R, O'Donnell M, Haber, PS, Day CA. (2021) Setting foot in private spaces: Extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines. Australian Professional Society on Alcohol and other Drugs (APSAD), Brisbane, 8-10 November 2021 (virtual).
9. Coupland H, Henderson C, Pritchard-Jones, J, Kao, S-C, Sheils, S, Nagy R, O'Donnell M, Haber, PS, Day CA. (2021) Setting foot in private spaces: Extending the hepatitis C cascade of care to automatic needle/syringe

- dispensing machines. Drug (Paper 105). *Drug and Alcohol Review*, 40 (Suppl. 1), S60.; DOI: 10.1111/dar.13384
10. Elizabeth Dale & Sharynne Hamilton. (2021). Strength-based approaches: mutual support, youth justice. Centre of Research Excellence: Indigenous Health and Alcohol. Camperdown/Virtual. 16 September
 11. Day CA. (2021) The ADMIT study: Linking people who use automatic needle/syringe dispensing machines with hepatitis C care. Presentation to NSW HIV and Related Program (HARP) managers. July 1, 2021 (virtual).
 12. Michael Doyle & Doug James. (2021). Treating alcohol dependence in rehab or prison. Centre of Research Excellence: Indigenous Health and Alcohol. Camperdown/Virtual. 29 July
 13. Michael Doyle, Annalee Stearne, Teagan Weatherall, Lynette Bullen, Jimmy Perry. (2021). Creating pathways for Aboriginal people to lead the way in alcohol research (symposia in a plenary session). National Indigenous Drug and Alcohol Conference (NIDAC). Glenelg. 23 - 26 March
 14. Michael Doyle, Jimmy Perry, Sharynne Hamilton, Robyn Williams. (2021) FASD and men (workshop). National Indigenous Drug and Alcohol Conference (NIDAC). Glenelg. 23 - 26 March
 15. Dunlop, A. J., Roberts, J., White, B., Haber, P. S., Cretikos, M., Attalla, D., ... & Lintzeris, N. (2021, November). Overview and findings of the unloct trial- implementing depot buprenorphine in new south wales correctional facilities
 16. Dunlop, A. J., White, B., Roberts, J., Graham, R., Ezard, N., Mcentyre, L. M. E., et al., & Haber, P. S. (2021, November). Understanding how long-acting depot buprenorphine impacts the high-risk post-release period-protocol for the release study
 17. Geiger B, Colledge S, Roxburgh A, Hocknull K, Bartlett M, Day CA, Shand F. (2021) Prevention, assessment and management of suicidality in clients attending drug and alcohol services (Paper 179). *Drug and Alcohol Review*, 40 (Suppl. 1), S73.; DOI: 10.1111/dar.13384.
 18. Haber, Paul. MJA Podcast 2021 Episode 40: Treating alcohol disorders in 2021. <https://www.mja.com.au/podcast/215/7/mja-podcasts-2021-episode-40-treating-alcohol-disorders-2021-professor-paul-haber>
 19. Haber, P. Morley, K.C. Genetic moderators of response to baclofen treatment. *Research Society on Alcoholism*, 2021.
 20. Hocknull K, Bartlett M, Roxburgh A Shand F Geiger B, Colledge S, Day CA, Jauncey M. (2021) Prevention, assessment and management of suicidality in clients attending drug and alcohol services (Paper 187). *Drug and Alcohol Review*, 40 (Suppl. 1), S80.; DOI: 10.1111/dar.13384
 21. Marianne Jauncey , Nico Clark, Chris gough, Amanda Roxburgh, Shelley Cogger, Mark Bartlett, Nathan Stam, Paul Dietze. (2021, November)The evolution of Supervised Injecting Facilities in Australia - A tale of three cities

22. Kylie Lee & Scott Wilson. (2021). Re-thinking how we ask about drinking. National Indigenous Drug and Alcohol Conference (NIDAC). Glenelg. 23 - 26 March
23. Kylie Lee. (2021). Re-thinking how we ask about drinking. Burnet Institute, Whole of Institute Seminar. Virtual. July
24. Kylie Lee. (2021). Re-thinking how we ask about drinking. Digital Health Information Network, University of Sydney. Virtual. October
25. Lintzeris, N., Dunlop, A. J., Haber, P. S., Lubman, D. I., Graham, R., Hutchinson, S., et al. & Tiberg, F. (2021, November). Overview and findings of the debut study: an open label randomised controlled trial of buvidal versus sublingual buprenorphine
26. Little, S. C., White, B., Moensted, M., Butler, K., Roberts, J., Howard, M., et al., & Dunlop, A. J. (2021, November). Health service and custodial staff acceptability of depot buprenorphine in new south wales correctional centres. in drug and alcohol review (vol. 40, pp. s100-s100).
27. Little S, Reid S, White B, Haber P, Day C. Client experience of depot-buprenorphine two years post implementation: Barriers to treatment and challenges of COVID-19. APSAD 2021
28. Little S, Tremonti C, White B, Reid S, Haber P, Day C. Public opioid dispensary clinic clients and their use of health services pre and post 2020 COVID-19 restrictions in Sydney, NSW. APSAD 2021
29. Logge, W., Morley, K.C. Haber, P. fMRI and rs-fMRI during baclofen treatment in alcohol use disorder. *Research Society on Alcoholism, 2021*
30. Louie, E., Giannopoulos, V., Uribe, G., Wood, K., Childs, S., Rogers, D., et al, & Morley, K. C. (2021, November). Geographic variations in Australian drug and alcohol services influence the implementation of the pathways to comorbidity care.
31. Morley, K.C. Haber, P. New Anticonvulsants Clinical Trials in AUD - Predictors and Modifiers of Response. *Research Society on Alcoholism, 2021.*
32. Nithyanandam L & Day CA. (2021) Improving access to treatment and support for women with substance use disorders while still living in the community (Paper 319). *Drug and Alcohol Review, 40 (Suppl. 1), S113.*; DOI: 10.1111/dar.13384
33. Reid S, Day CA, Demirkol A, Bowen D and Haber PS Clinical Indicators for Substance Use in Pregnancy and Parenting Services: A Scoping Review, in *Australian Professional Society on Alcohol and other Drugs (APSAD). 2021: Brisbane, Australia.*
34. Reid S, Day CA, Demirkol A, Bowen D and Haber PS. Mothers, injecting drug use, hepatitis C and integrated healthcare. *International Conference on Integrated Care (ICIC21) Virtual Conference May 2021*
35. Riordan, B. C., Moradi, S., Winter, T., Carey, K. B., Conner, T. S., Jang, K., et al, & Scarf, D. (2021, November). A combined web-based and ecological

momentary intervention for incoming first-year university students: a three-arm randomised

36. Schwantes-An T-H, Morgan T, Seth D and the GenomALC Consortium. Polygenic Risk Score for risk of developing Alcohol-associated Liver Cirrhosis among heavy drinkers. Poster Session Title: Genomics and Precision Medicine. The Liver Meeting-American Association for Study of Liver Diseases (AASLD), Boston
37. Seth, D. Media release 24 Oct 2021: by Centenary Institute; QIMR Berghofer; J Hepatol; MedicalExpress; LabDownunder
38. Seth, Devanshi. Common pathways activated in the liver and adipose tissue may contribute towards AALD pathogenesis. Oral presentation for Symposium "Emerging roles of adipose tissue in alcohol-associated liver disease at the 44th Annual RSA Scientific Meeting/ISBRA Congress, USA. 19th-23rd Jun 2021 (virtual).
39. Seth, D. 2021. National Institute on Alcohol and Alcoholism (NIAAA) Intramural/extramural Fall Seminar Series, Bethesda, USA. 'Genomics of Alcohol Cirrhosis in the GenomAlc Consortium: Pathways to Disease and Polygenic Prediction.' Oct 14th 2021 (virtual).
40. Seth, D. 2021. Gordon Research Conference - Alcohol-Induced End Organ Diseases: Developing Molecular Pathways into Therapeutic Opportunities for Alcohol-Associated Diseases. 'Clinical relevance of underlying genetics in patients with high alcohol use and cirrhosis: the GenomALC study'. Ventura, CA, USA. 24-29 October 2021 (virtual/hybrid).
41. Seth, D. 2021. American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021, Boston USA. 'Genetic Basis of Alcoholic Liver Disease' SESSION TITLE: Basic Research Workshop - Part II (From Gene Discovery to New Insights into Liver Disease Pathogenesis) Nov 12-15, 2021 (hybrid-virtual).
42. Seth, D. 2021. 44th Annual RSA Scientific Meeting / ISBRA Congress, USA. 'Common pathways activated in the liver and adipose tissue may contribute towards AALD pathogenesis' in 'Emerging roles of adipose tissue in AALD' symposium. 19-23 Jun 2021 (virtual).
43. Seth, D. https://www.centenary.org.au/cen_news/genetic-risk-test-developed-to-predict-alcohol-related-cirrhosis-of-the-liver/
44. Seth, D. <https://medicalxpress.com/news/2021-10-genetic-alcohol-related-cirrhosis-liver.html>
45. Seth, D. <https://twitter.com/QIMRBerghofer/status/1452512412343549954>
46. Seth, D. <https://twitter.com/labdownunder/status/1452772102667374594>
47. Fathima Shihana, Pradeep Cholan, Stefan Oehlers, Devanshi Seth. Growing evidence of lipid genetics in cirrhosis: investigating the role of genes involved in lipid biology in zebrafish models of fatty liver. Gordon Research Conference - Alcohol-Induced End Organ Diseases, "Novel Molecular Pathways That Contribute to Alcohol-Induced Tissue Dysfunction". 24-29 October 2021 (hybrid).

48. Ling, Rod, Bethany White, Jill Roberts, Michelle Cretikos, Mark Howard, Paul S. Haber, Nicholas Lintzeris, Adrian J. Dunlop, and Andrew Searles (2021, November). Depot buprenorphine as an opioid agonist therapy in new south wales correctional centres: a costing model.
49. Roxburgh, A., Drummer, O. (2021). Investigating the acute pathology processes among MDMA-related deaths in Australia
50. Tremonti, C., Perananthan, V., Buckley, N., Blogg, J., Jamshidi, N., & Haber, P. S. (2021, November). Micro-dosing with buprenorphine to transfer from methadone to buprenorphine-a non-randomised open label clinical trial
51. Teagan Weatherall & Gemma Purcell-Khodr. (2021). Alcohol dependence in primary care or community. Centre of Research Excellence: Indigenous Health and Alcohol. Camperdown/Virtual. 18 November
52. Winter DT, Haber PS, Lintzeris N, Monds L, Day CA. (2021) Driving and transport-related behaviours and knowledge of opioid agonist treatment clients in New South Wales, Australia (Paper 147). Drug and Alcohol Review, 40 (Suppl. 1), S153.; DOI: 10.1111/dar.

Staff

Academic staff (n=24)

- Professor Andrew Baillie, Professor, Allied Health (USYD); Clinical Psychologist (SLHD)
- Professor Nicholas Buckley, Professor, Clinical Pharmacology (USYD); Clinical Toxicologist
- Dr Kate Chitty, Research Fellow
- Professor Kate Conigrave, Senior Staff Specialist (SLHD); Director, Centre of Research Excellence in Indigenous Health and Alcohol (USYD); Conjoint Professor, Addiction Medicine (USYD)
- Dr James Conigrave, Research Fellow, Speciality of Addiction Medicine (USYD)
- Professor Andrew Dawson, Senior Staff Specialist (SLHD); Clinical Professor, Pharmacology and Toxicology (USYD)
- Associate Professor Carolyn Day, Research Education Academic Director, Faculty of Medicine and Health (USYD)
- Dr Michael Doyle, Senior Research Fellow, Centre of Research Excellence in Indigenous Health and Alcohol (USYD)
- Professor Paul Haber, Clinical Director, Drug Health Services (SLHD); Head, Speciality of Addiction Medicine (USYD)
- Dr Nazila Jamshidi, Staff Specialist (SLHD); Clinical Senior Lecturer, Central and Western Clinical Schools
- Associate Professor Kylie Lee; Deputy Director, Centre of Research Excellence in Indigenous Health and Alcohol (USYD); Visiting Fellow Centre for Alcohol Policy Research (LTU); Adjunct Associate Professor, National Drug Research Institute (Curtin University)
- Dr Warren Logge, Post-doctoral Research Officer
- Dr Maja Moensted, Post-doctoral Research Officer
- Dr Lauren Monds, Academic Fellow, Specialty of Addiction Medicine (USYD)
- Associate Professor Kirsten Morley, Specialty of Addiction Medicine (USYD)
- Dr Firouzeh Noghrecchi, Statistician
- Dr Jacques Raubenheimer, Statistician

- Dr Sharon Reid, Career Medical Officer (SLHD); Senior Lecturer, Specialty of Addiction Medicine and School of Public Health (USYD)
- Dr Ben Riordan, Post-doctoral Research Officer
- Dr Amanda Roxburgh, Post-doctoral Research Associate
- Clinical Associate Professor Devanshi Seth, Principal Scientist (SLHD); Head, Alcoholic Liver Disease Laboratory (Centenary Institute); Specialty of Addiction Medicine and Specialty of Clinical Medicine (USYD)
- Dr Bethany White, Research Manager, Clinical lecturer
- Adjunct Associate Professor Scott Wilson, Joint-Director, Centre of Research Excellence in Indigenous Health and Alcohol (USYD)
- Dr Danni Zheng, Statistician/Epidemiologist

Professional staff (n=29)

- Claire Adams, Research Assistant
- Zein Albedeen Ali, Research Assistant
- Susan Anderson, Clinical Research Nurse
- Farah Al Ansari, Research Assistant
- Mustafa Al Ansari, Research Assistant
- Annabelle Chidiac, Research Assistant
- Karen Conroy, Clinical Research Nurse
- Dr Heidi Coupland, Post-doctoral Research Officer
- Elizabeth Dale, Research Assistant
- Bebe DeSouza, Research Assistant
- Dr Monika Dzikowska, Research Program Manager
- Brennan Geiger, Research Assistant
- Dr Vicki Giannopoulos, Research Officer
- Holly Hardress, Research Assistant
- Tristan Hurzeler, Research Assistant
- Sophia Little, Research Officer
- Summer Loggins, Research Administrative Assistant
- Eva Louie, Research Assistant
- Zara Mills, Research nurse
- Dr Janaka Pushpakumara, Research Officer, Psychologist
- Taleah Reynolds, Research Administration Assistant
- Susan Rombouts, Research Assistant
- Maria Uribe Guajardo, Research Officer
- Dr Chris Tremonti, Advanced Trainee
- Dr Anastasia Volovets, Staff Specialist in Gastroenterology and Hepatology, Addiction Medicine and Toxicology
- Natalie White, Research Assistant
- Daniel Winter, Research Officer
- Katie Wood, Research Officer
- Catherine Zheng, Research Assistant

Higher Degree Students (PhD and MPhil) (n=26)

- Mustafa Al Ansari, PhD student
- Dr Angela Chiew, PhD student
- Elizabeth Dale, PhD student
- Monika Dzikowska, PhD student

- Fathima Shihana Haniffa Salahudeen, PhD student
- Kristie Harrison, PhD student
- Tristan Hurzeler, PhD student
- Douglas James, PhD student
- Winston Kardell, PhD student
- So Bi Kim, PhD student
- Jessy Lim, PhD student
- Sophia Little, PhD student
- Eva Louie, PhD student
- Rhys Mantell, PhD student
- Erica Martin, PhD student
- Tammy Merrick, PhD student
- Van Long Nguyen, PhD student
- Dr Varan Perananthan, PhD student
- Gemma Purcell-Khodr, PhD student
- Annalee Stearne, PhD student
- Dr Natalie Thurtle, PhD student
- Christopher Tremonti, PhD student
- Teagan Weatherall, PhD student
- Susan Welch, PhD student
- Daniel Winter, PhD student
- Amelia Woods, PhD student

Masters/Other Post Graduate Students (n=16)

- Rachel Braude, Doctor of Medicine
- Lynette Bullen, Rural Capacity Building Program
- Zachary Bryant, Master Public Health
- Felicia Cao, Doctor of Medicine
- Kate Hocknull, Master Public Health
- Kathryn Ruth Kiefhaber, Doctor of Medicine
- Summer Loggins, LLB
- Hannah Mogatra, Honours
- Rengen Parlane, Doctor of Medicine
- Taleah Reynolds, Grad Dip Indigenous Health Promotion
- Aiden Roberts, Doctor of Medicine
- Ameilia Russell, Master Public Health
- Olya Ryjenko, Master Public Health
- Aayushi Talwar, Doctor of Medicine
- Vincent Tran, Doctor of Medicine
- Tim Weatherall, Grad Dip Indigenous Health Promotion



Translational Research
Alcohol • Drugs • Toxicology

Edith Collins Centre
King George V Building
Missenden Road
Camperdown
NSW 2050